The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributions from multiple investigators, science recognized by the 2017 Harrington Award Prize for Innovation in Medicine
Rahman, I., Mulier, B., Gilmour, P.S., Jeffery, P.K
External resources FDA Drug Safety and Availability - Official safety communications and labeling updates for tirzepatide CDC Urinary Tract Infection Information - Evidence-based UTI prevention and treatment guidance American Urological Association Guidelines - Clinical guidelines for recurrent UTI management ClinicalTrials.gov - Complete database of SURPASS and SURMOUNT tirzepatide trial results National Institute of Diabetes and Digestive and Kidney Diseases - Comprehensive UTI resource from NIH For people serious about understanding how their medications affect every aspect of their health, SeekPeptides offers the most comprehensive resource available for evidence-based peptide and medication guidance
Unlike FDA-approved GLP-1s dispensed at pharmacies, compounded semaglutide is not held to strict quality standards
This dual effect on both sides of the energy balance equation is why retatrutide produced the highest weight loss percentages of any single-agent trial
